A kind of prasugrel hydrochloride compound

Abstract

The present invention belongs to the technical field of medicines, and in particular relates to a prasugrel hydrochloride compound. Prasugrel is a new generation of potent thianthrene-pyridine antiplatelet drug. By observing on healthy volunteers and application in stable angina pectoris and acute coronary syndrome interventional operations, faster and stronger and more durable antiplatelet effect of the prasugrel hydrochloride compound, compared with that of clopidogrel, is found, the incidence of ischemic events can be significantly reduced, but the risk of bleeding is increased. In clinical use, more attention must be paid for identification of thrombosis high-risk patients and high-bleeding-risk groups.

Description

technical field

[0001] The invention belongs to the field of medical research, in particular to a prasugrel hydrochloride compound. Background technique

[0002] In February 2009, the European Commission approved a new oral antiplatelet drug, prasugrel, jointly developed by Daiichi-Sankyo and EliLilly, for the prevention of patients who have received emergency and will undergo delayed percutaneous coronary intervention. Atherothrombosis events in patients with acute coronary syndrome. This is the first time Prasugrel has been approved globally.

[0003] Prasugrel is a new orally effective thienopyridine drug. Like clopidogrel, prasugrel is also an inactive prodrug, which can irreversibly inhibit the P2Y12 adenosine diphosphate receptor on platelets after being metabolized by cytochrome P450 enzymes to active metabolites. Prasugrel is more effective than clopidogrel, which can be explained by its improved pharmacokinetic properties: Prasugrel has a higher conversion rate o...

Images